Pathogenetic treatment with strontium ranelate in women with postmenopausal osteoporosis

Abstract

The possibility of recovering the functional status is now considered as an integral part of the development of new treatment strategies for chronic
diseases, including osteoporosis (OP). The possibility to optimize the treatment of OP, by exerting a more physiological effect on bone and
simultaneously reducing the increased bone resorption and formation, is highly urgent. The system of osteoprotegerin (OPG), receptor activator
of nuclear factor-κ B and its ligand has been confirmed to play a central role in the regulation of bone metabolism. At the same time, there
is strong evidence that OPG performs a key function in bone metabolism regulation, by suppressing the differentiation of osteoclasts (OC) and
reducing their activity. The synthesis of OPG decreases with age in postmenopausal and glucocorticoid-induced OP. Thus, more effective bone
protection needs to elevate the level of OPG, by stimulating its synthesis. Bivalos facilitates the replication of osteoblasts and the higher expression
of OPG, resulting in a reduction in the differentiation and activity of OC. Thus, Bivalos positively uncouples the interrelated processes of
bone metabolism. A combination of the bone-forming and antiresorptive effects of the agent leads to the recovery of bone balance in favor of
bone formation. Strontium ranelate should be presently considered as a first-line safe and effective agent for the long-term treatment of women
with postmenopausal OP.